Antidepressants and Suicide Risk in Youth
Yes, antidepressants carry a small but statistically significant increased risk of suicidal ideation and suicide attempts in children and adolescents, but this risk is substantially outweighed by their therapeutic benefits, particularly for anxiety disorders and OCD, and to a lesser extent for depression. 1
The Evidence on Risk
The FDA black-box warning issued in 2004 was based on meta-analyses showing a modest increase in suicidal ideation and attempts (but no completed suicides) in pediatric patients treated with antidepressants. The absolute risk increase is approximately 0.7-0.9% across all indications 2, 3. This translates to a number needed to harm of 143 (95% CI, 77-1000) 2.
Critical context: There were zero completed suicides in any of the analyzed trials 2, 3. The risk is for suicidal ideation and attempts, not death by suicide.
The Evidence on Benefit
The therapeutic benefit varies substantially by indication 2:
- Non-OCD anxiety disorders: Risk difference 37.1% (NNT = 3)
- OCD: Risk difference 19.8% (NNT = 6)
- Major depressive disorder: Risk difference 11.0% (NNT = 10)
The benefit-to-risk ratio is most favorable for anxiety disorders and OCD, and more modest but still positive for depression. For depression specifically, the NNT of 10 versus NNH of 143 means you would need to treat approximately 14 patients to see one benefit for every potential harm 2.
Clinical Management Algorithm
1. Pre-Treatment Discussion
Inform patients and families about 1:
- The small increased risk of suicidal ideation/attempts (approximately 1 in 143)
- The absence of completed suicides in clinical trials
- The risk is highest in the first few months and with dose changes
- Starting at higher doses increases risk 1
2. Monitoring Schedule
1 specify:
- Week 1: In-person assessment (ideal) or telephone contact
- Ongoing: Regular monitoring especially during the first few months and at any dose changes
- At each contact, assess:
- Ongoing depressive symptoms
- Suicide risk specifically
- Adverse effects
- Treatment adherence
- Environmental stressors
3. Medication Selection
- For depression in children <12 years: Only fluoxetine has demonstrated benefit 2
- For depression in adolescents ≥12 years: Fluoxetine or sertraline are preferred 4
- Start at normal starting doses, not higher doses to minimize risk 1
4. High-Risk Situations Requiring Immediate Treatment
Do not delay antidepressant treatment in a depressed and actively suicidal teenager due to concerns about manageable side effects 5. The risk of untreated severe depression with active suicidality far exceeds the small risk of treatment-emergent suicidal ideation.
Important Caveats
Age matters: The risk of treatment-emergent suicidality is highest in patients under 25 years, decreasing after age 30-40 6. Children under 12 years may be at higher risk and were less likely to be monitored in real-world practice 7.
Indication matters: Patients treated for depression require more vigilant monitoring than those treated for anxiety or OCD, as they were more likely to be monitored in clinical practice 7. However, all patients on SSRIs require monitoring regardless of indication 1.
The alternative is worse: Untreated depression itself carries substantial suicide risk. The evidence suggests that the benefits of treating depression, anxiety, and OCD with antidepressants substantially outweigh the small risk of treatment-emergent suicidal ideation 2, 8.
Behavioral activation: Watch for development of agitation, restlessness, or behavioral activation, which may signal increased risk 1.